The abstract is read at the publisher; the summary is JClub's.
In women with breast cancer receiving moderately or highly emetogenic chemotherapy, adding olanzapine or prochlorperazine in Cycle 2 reduced persistent nausea versus placebo, with olanzapine improving maximum nausea by -0.59 (P=.02).
- Why it matters: Even with guideline-based prophylaxis, persistent chemotherapy-induced nausea remains common, and phase 3 head-to-head evidence for olanzapine versus prochlorperazine as escalation is limited.
- What they did: In a multicenter, randomized, double-blind, placebo-controlled phase 3 trial at 23 NCORP community oncology sites, women with Cycle 1 nausea score ≥3 were assigned in Cycle 2 to placebo, prochlorperazine 10 mg every 8 hours (Days 1-4), or olanzapine 10 mg daily (Days 1-4) added to netupitant/palonosetron plus dexamethasone.
- The result: Average nausea improved versus placebo with prochlorperazine (-0.44; P=.01) and olanzapine (-0.57; P=.001), while olanzapine also improved FACT-G quality-of-life versus placebo (4.91; P=.006) and prochlorperazine (5.80; P=.001), with mostly grade 1-2 adverse events and no toxicity-related discontinuations.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.